Literature DB >> 31741614

Correlation of Day 8 Steroid Response with Bone Marrow Status Measured on Days 14 and 35, in Patients with Acute Lymphoblastic Leukemia Being Treated with BFM Protocol.

Girish Kamat1, Kannan Subramanian2, Shashikant Apte2.   

Abstract

Berlin-Frankfurt-Munster (BFM) protocol is commonly used in India for treatment of acute lymphoblastic leukemia (ALL). The present study was conducted to correlate day 8 steroid response with bone marrow status (by morphology and flow cytometry) at day 14 and day 35 of treatment. It was a prospective study which included all newly diagnosed ALL patients who visited hospital between March 2013 and February 2015 i.e. 2 years. On 8th day, the number of lymphoblasts was counted in the peripheral blood. Based on the number of blasts patients were classified as good steroid responders and poor steroid responders. Following pre-induction steroids patients were given induction therapy. During this phase on day 14 and day 35 bone marrow (BM) aspiration study was done. Later day 8 steroid response, Day 14 BM status and day 35 BM status were correlated. Results showed that there was a statistically significant correlation between day 8 steroid response and day 14 BM status (both by morphology and flow cytometry). There was no statistically significant correlation between day 8 steroid response and day 35 BM status (both by morphology and flow cytometry). There was no statistically significant correlation between day 14 and day 35 BM status (both by morphology and flow cytometry). Sensitivity and specificity of morphological evaluation of BM was much lower compared to minimal residual disease assessment by flow cytometry. There is a need to incorporate flow cytometry in risk stratification of patients who are being treated with BFM 2002 protocol. © Indian Society of Hematology and Blood Transfusion 2019.

Entities:  

Keywords:  Acute lymphoblastic leukemia; BFM protocol; Day 8 steroid response; Minimal residual disease

Year:  2019        PMID: 31741614      PMCID: PMC6825086          DOI: 10.1007/s12288-019-01119-4

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  11 in total

1.  Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.

Authors:  Melchior Lauten; Anja Möricke; Rita Beier; Martin Zimmermann; Martin Stanulla; Barbara Meissner; Edelgard Odenwald; Andishe Attarbaschi; Charlotte Niemeyer; Felix Niggli; Hansjörg Riehm; Martin Schrappe
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].

Authors:  U zur Stadt; D O Harms; S Schlüter; N Jorch; H J Spaar; W Nürnberger; S Völpel; P Gutjahr; M Schrappe; G Janka; H Kabisch
Journal:  Klin Padiatr       Date:  2000 Jul-Aug       Impact factor: 1.349

3.  Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL.

Authors:  Marja J Willemse; Taku Seriu; Klaudia Hettinger; Elisabetta d'Aniello; Wim C J Hop; E Renate Panzer-Grümayer; Andrea Biondi; Martin Schrappe; Willem A Kamps; Guiseppe Masera; Helmut Gadner; Hansjoerg Riehm; Claus R Bartram; Jacques J M van Dongen
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

4.  Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study.

Authors:  M J Borowitz; D J Pullen; J J Shuster; D Viswanatha; K Montgomery; C L Willman; B Camitta
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

5.  Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.

Authors:  A Reiter; M Schrappe; W D Ludwig; W Hiddemann; S Sauter; G Henze; M Zimmermann; F Lampert; W Havers; D Niethammer
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

6.  Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002.

Authors:  Jan Stary; Martin Zimmermann; Myriam Campbell; Luis Castillo; Eduardo Dibar; Svetlana Donska; Alejandro Gonzalez; Shai Izraeli; Dragana Janic; Janez Jazbec; Josip Konja; Emilia Kaiserova; Jerzy Kowalczyk; Gabor Kovacs; Chi-Kong Li; Edina Magyarosy; Alexander Popa; Batia Stark; Yahia Jabali; Jan Trka; Ondrej Hrusak; Hansjörg Riehm; Giuseppe Masera; Martin Schrappe
Journal:  J Clin Oncol       Date:  2013-12-16       Impact factor: 44.544

7.  The prognostic significance of minimal residual disease in adult Egyptian patients with precursor acute lymphoblastic leukemia.

Authors:  Mohamed A Samra; Hossam K Mahmoud; Thoraya M Abdelhamid; Nahla M El Sharkawy; Yasser H Elnahass; Mossaad Elgammal; Rafaat M Abdelfattah; Salem Eid; Fayek M Ghaleb; Azza M Kamel
Journal:  J Egypt Natl Canc Inst       Date:  2013-06-29

Review 8.  Epidemiology of childhood cancer in India.

Authors:  R S Arora; T O B Eden; G Kapoor
Journal:  Indian J Cancer       Date:  2009 Oct-Dec       Impact factor: 1.224

9.  Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction.

Authors:  R Ratei; G Basso; M Dworzak; G Gaipa; M Veltroni; P Rhein; A Biondi; M Schrappe; W-D Ludwig; L Karawajew
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

10.  Childhood acute lymphoblastic leukemia in India: an approach to management in a three-tier society.

Authors:  M Chandy
Journal:  Med Pediatr Oncol       Date:  1995-09
View more
  1 in total

1.  Prognostic Relevance of Expression of EMP1, CASP1, and NLRP3 Genes in Pediatric B-Lineage Acute Lymphoblastic Leukemia.

Authors:  Jay Singh; Sarita Kumari; Mohit Arora; Deepak Verma; Jayanth Kumar Palanichamy; Rajive Kumar; Gunjan Sharma; Sameer Bakhshi; Deepam Pushpam; M Shadab Ali; Amar Ranjan; Pranay Tanwar; Shyam S Chauhan; Archna Singh; Anita Chopra
Journal:  Front Oncol       Date:  2021-03-05       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.